Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

13.76 -0.21 (-1.54%)

Streaming Delayed Price Updated: 10:45 AM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

September 2022 Stock Considerations ↗

September 08, 2022

Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago.

Via Talk Markets

Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?

September 03, 2022

Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,...

Via MarketBeat

Stocks That Hit 52-Week Lows On Thursday ↗

September 01, 2022

On Thursday, 529 companies set new 52-week lows.

Via Benzinga

Viatris: Q2 Earnings Insights ↗

August 08, 2022

Viatris (NASDAQ:VTRS) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Viatris ↗

May 10, 2022

Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:

Via Benzinga

This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems ↗

August 24, 2022

From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle.

Via Benzinga

Recession Investing: 5 High Yield Dividend Stocks For A Downturn ↗

August 03, 2022

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus ↗

May 09, 2022

Via Benzinga

Recap: Viatris Q1 Earnings ↗

May 09, 2022

Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label ↗

April 13, 2022

Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is

Via Benzinga

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

High Dividend 50: Viatris ↗

March 25, 2022

Viatris is currently offering an above-average dividend yield of 4.4%. The company has posted GAAP losses in each of the last two years but its payout ratio is only 13% using adjusted EPS.

Via Talk Markets

7 High-Quality Dividend Stocks With High Yields ↗

June 07, 2022

These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments.

Via InvestorPlace

Looking Into Viatris's Return On Capital Employed ↗

June 03, 2022

According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4.

Via Benzinga

Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike

May 31, 2022

Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood...

Via FinancialNewsMedia

Current Report: Viatris ↗

May 20, 2022

Viatris Inc’s price per share was $11.68 as of yesterday's market close. One year ago its price was $15.59.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022 ↗

May 10, 2022

Upgrades

Via Benzinga

3 Top S&P 500 Stock Market Gainers Today ↗

May 09, 2022

Hard-hit stocks led S&P 500 winners. Commodity stocks were the big losers.

Via Investor's Business Daily

27 Recession-Resistant Stocks To Look At Now ↗

May 09, 2022

When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not...

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

Pfizer: What Comes After the Covid-19 Fire? ↗

April 21, 2022

Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles.

Via InvestorPlace

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Biogen’s Aduhelm Crashes the Biotech Sector ↗

April 13, 2022

Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock.

Via InvestorPlace

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

7 Cheap Stocks to Buy Now if You Have $100 to Spend ↗

March 22, 2022

The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks.

Via InvestorPlace

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill ↗

March 17, 2022

Via Benzinga

7 Drug Stocks to Consider After the Viatris Plunge ↗

March 10, 2022

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

Via InvestorPlace

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗

March 09, 2022

Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.